Introduction
============

Cancer may be associated with stroke. In a large cohort study, the 6-month cumulative incidence of ischemic stroke was significantly higher in patients with cancer than in matched controls (3.0% vs. 1.62%) \[[@b1-jos-2020-00619]\]. Nonbacterial thrombotic endocarditis (NBTE) is characterized by noninfectious vegetation on the cardiac valves \[[@b2-jos-2020-00619]\]. NBTE is a cause of stroke and most frequently develops in patients with systemic cancer \[[@b3-jos-2020-00619],[@b4-jos-2020-00619]\].

Most information on NBTE in stroke is derived from case reports or post-mortem studies because of its rarity \[[@b5-jos-2020-00619]-[@b8-jos-2020-00619]\]. Although patients with acute stroke and active cancer are known to have a substantial short-term risk of recurrent stroke \[[@b9-jos-2020-00619]\], the outcomes of stroke patients with cancer-associated NBTE are not well known. In addition, the pathomechanism of NBTE is unknown. However, pathological studies have shown that the vegetation and thrombi retrieved from stroke patients with NBTE have very high platelet fractions \[[@b10-jos-2020-00619],[@b11-jos-2020-00619]\]. Further, cancer is known to activate platelets, which play an important role in metastasis \[[@b12-jos-2020-00619]\]. These findings suggest a potential association between NBTE and metastasis. Previous case reports and post-mortem studies have shown frequent occurrences of metastasis in patients with NBTE. However, information on the presence of metastasis is insufficient in many cases \[[@b13-jos-2020-00619]-[@b16-jos-2020-00619]\]. Therefore, the association between NBTE and metastasis remains uncertain.

We hypothesized that development of NBTE has a relationship with metastasis. In this study, we investigated association between NBTE and metastasis, and the mortality and occurrence of stroke events for 6 months following an initial stroke in patients with cancer-associated NBTE.

Methods
=======

Study population
----------------

This retrospective study used a hospital-based prospective cohort of consecutively enrolled patients with ischemic stroke within 7 days of symptoms onset. Routine evaluations performed were as follows: standard blood tests including D-dimer; brain magnetic resonance imaging (MRI) and/or computed tomography (CT) and cerebral angiography (magnetic resonance angiography, CT angiography, or conventional angiography); Holter monitoring or continuous electrocardiography monitoring during admission in the stroke unit; and transesophageal echocardiography (TEE) and/or transthoracic echocardiography (TTE). TEE was not performed in patients with decreased consciousness, aphasia, impending brain herniation, poor systemic conditions, severe swallowing difficulty, tracheal intubation, or when informed consent could not be obtained \[[@b17-jos-2020-00619]\].

The study hospital is a tertiary university hospital with a dedicated cancer center where patients with cancer routinely undergo extensive evaluations for the presence of metastasis. When cancer or NBTE is diagnosed during admission, patients are referred to oncologists for further evaluation and treatment.

This study included consecutive patients with active cancer who were registered between January 2010 and December 2018 and who underwent echocardiography. Active cancer was defined as cancer that was diagnosed within 6 months, required chemotherapy or surgical treatment within 6 months, or was recurrent, metastatic, or inoperable \[[@b18-jos-2020-00619]\]. Patients with brain malignancy or hematologic malignancy were excluded. The cohort and this study were approved by the Institutional Review Board of the Yonsei University Health System. The need for an informed consent was waived due to the retrospective nature of the study.

Study group
-----------

Because the study participants had active cancer, patients were categorized into those with NBTE, those with cryptogenic etiology, and those with determined etiology \[[@b11-jos-2020-00619]\]. NBTE was determined based on formal reports by cardiologists who diagnosed vegetation based on echocardiographic examinations. Five patients with NBTE and co-existing atrial fibrillation were classified into the NBTE group. Twenty-one patients with a patent foramen ovale without venous thrombosis and other determinable etiologies were classified into cryptogenic etiology group.

Outcome assessments
-------------------

All patients were regularly followed up after discharge by neurologists and clinical research assistants in the outpatient clinic using face-to-face interviews or by a telephonic interview using a structured questionnaire \[[@b19-jos-2020-00619]\]. We reviewed the medical records to obtain information on mortality and cause of death. The cause of death was categorized as stroke-related, cancer-related, or others/unknown \[[@b20-jos-2020-00619]\]. Information on the occurrence of any new stroke events (cerebral infarction or intracerebral hemorrhage \[ICH\]) after the initial cerebral infarction was also obtained from medical records. The diagnosis of stroke was based on brain MRI and/or CT results.

Statistical analysis
--------------------

Variables were expressed as mean±standard deviation, median (interquartile range), or number (percentage), as appropriate. Baseline characteristics among the groups were compared using one-way analysis of variance or the Kruskal-Wallis test for continuous variables and the chi-square test or Fisher's exact test for categorical variables. *Post hoc* analysis was performed using Bonferroni's correction or Dunn's test. Kaplan-Meier estimates and log-rank tests were performed (adjusted by Bonferroni's correction) for mortality, occurrence of stroke, and composite outcomes of mortality and stroke. To determine whether the presence of NBTE was associated with composite events of mortality and stroke, we performed multivariate Cox proportional hazard regression analyses. As all patients with NBTE had metastasis and 90% of patients with NBTE had multiple territory infarctions, we constructed two different multivariate regression models to avoid multicollinearity. Model 1 included the presence of NBTE and Model 2 included metastasis and multiple territory infarctions. All statistical analyses were performed using R statistical software version 3.5.1 (<http://www.R-project.org>). A *P*\<0.05 was considered statistically significant.

Results
=======

During the 9-year study period, 289 patients with acute ischemic stroke and active cancer were registered to the cohort. Of those, 245 patients (84.8%) underwent echocardiography and were included in this study (123 patients underwent both TEE and TTE, 25 patients underwent TEE only, and 97 patients underwent TTE only). The mean age of the included patients was 68.7±10.7 years, and 136 patients (55.5%) were men. Compared to patients who underwent echocardiography, those who did not undergo echocardiography were younger, had fewer atrial fibrillation and higher National Institutes of Health Stroke Scale (NIHSS) scores. Cancer types were not different between patients who did or did not undergo echocardiography ([Supplementary Table 1](#SD1-jos-2020-00619){ref-type="supplementary-material"}).

Comparison between the groups
-----------------------------

Of the 245 patients, 20 patients (8.2%) had NBTE, 96 (39.2%) had a cryptogenic etiology, and 129 (52.7%) had determined etiologies. In patients with determined etiologies, those with cardioembolism were 51, those with large artery atherosclerosis were 46, and those with two or more causes were 19 ([Supplementary Table 2](#SD2-jos-2020-00619){ref-type="supplementary-material"}). Of 150 patients (61.2%) with metastasis, NBTE was diagnosed in 20 patients (13.3%). Compared with patients with determined etiologies, those with NBTE were younger, had more frequent multiple vascular territory involvement, lower platelet counts, lower fibrinogen levels, and higher D-dimer levels ([Table 1](#t1-jos-2020-00619){ref-type="table"}).

Metastasis, cancer type, and NBTE
---------------------------------

All 20 patients with NBTE had metastasis, and NBTE was not detected in patients without metastasis. The presence of metastasis was significantly higher in patients with NBTE (100%) than in those with stroke with a cryptogenic etiology (69.8%; *P*=0.014 after Bonferroni's correction) or those with a determined etiology (48.8%; *P*\<0.001 after Bonferroni's correction) ([Table 1](#t1-jos-2020-00619){ref-type="table"}). The cancer type was not significantly different among the three groups ([Table 1](#t1-jos-2020-00619){ref-type="table"}).

Six-month mortality and stroke events
-------------------------------------

All patients were followed up for 6 months after the initial stroke event. During the follow-up, 127 patients (51.8%) developed stroke events and/or died (110 \[44.9%\] died and 55 \[22.4%\] patients experienced stroke events). The median survival of patients with NBTE was 44.5 days, and event-free survival of composite outcomes of mortality and stroke was 36 days. During the 6-month follow-up, 90% (18/20) patients with NBTE died or developed stroke, while only 38.8% patients with a determined etiology died or developed stroke (50/129, *P*\<0.001) ([Table 2](#t2-jos-2020-00619){ref-type="table"}).

Compared to event-free patients, those with events (mortality or stroke) were younger and had lower body mass indices and higher initial NIHSS scores. They also had lower hemoglobin levels, platelet counts, and fibrinogen levels, and higher white blood cell counts and D-dimer levels ([Table 3](#t3-jos-2020-00619){ref-type="table"}). Metastasis and multiple vascular territory involvements were more common in patients with mortality or stroke events. Cancer type was also different between patients with or without events ([Table 3](#t3-jos-2020-00619){ref-type="table"}).

In the Kaplan-Meier survival analysis, the 6-month mortality was different among the three groups (*P*\<0.001). Patients with NBTE showed lower 6-month survival probability, lower stroke-free probability, and lower event-free probability than those with cryptogenic or determined etiologies ([Figure 1](#f1-jos-2020-00619){ref-type="fig"}). Mortality, stroke events, and composite outcomes were more common in patients with a cryptogenic etiology than in those with a determined etiology ([Figure 1](#f1-jos-2020-00619){ref-type="fig"}).

Causes of death
---------------

During the follow-up, more patients with NBTE died (16/20 \[80.0%\]) compared to those with a cryptogenic etiology (52/96 \[54.2%\]) and a determined etiology (32/129 \[32.6%\]) (*P*\<0.001). Causes of death were cancer-related in 83 (75.5%), stroke-related in 21 (19.1%), and other/unknown in six (5.5%) patients. The cause of death did not significantly differ among the three groups (*P*=0.307) ([Table 2](#t2-jos-2020-00619){ref-type="table"}).

Stroke events
-------------

During the 6-month follow-up, stroke events occurred in 55/245 (22.4%) of patients; 53 (21.6%) with ischemic stroke and two (0.8%) with ICH. Stroke was diagnosed using diffusion-weighted imaging in 49 patients (89.1%) and by CT in five patients (9.1%). The type of imaging was uncertain in one patient who was diagnosed at another hospital (1.8%). Stroke events occurred most frequently in patients with NBTE (10/20, 50%), followed by those with a cryptogenic etiology (24/96, 25.0%) and those with a determined etiology (21/129, 16.3%) ([Table 2](#t2-jos-2020-00619){ref-type="table"}). Mortality was more frequent in patients with stroke events than in those without (69.1% \[38/55\] vs. 37.9% \[72/190\], *P*\<0.001).

Factors associated with mortality and stroke events
---------------------------------------------------

In the multivariate Cox proportional hazard analysis, female sex and a lower body mass index were associated with composite outcomes of mortality and stroke both in Model 1 and Model 2. The composite outcomes were independently associated with the presence of NBTE (hazard ratio \[HR\], 1.941; 95% confidence interval \[CI\], 1.052 to 3.690) ([Table 4](#t4-jos-2020-00619){ref-type="table"}, Model 1). The presence of metastasis (HR, 2.870; 95% CI, 1.648 to 4.996) and the involvement of multiple vascular territories (HR, 2.524; 95% CI, 1.570 to 4.058) were also independently associated with the composite outcomes ([Table 4](#t4-jos-2020-00619){ref-type="table"}, Model 2).

Discussion
==========

In this study, NBTE was diagnosed in approximately one of 11 stroke patients with active cancer. NBTE was also found exclusively in patients with metastasis. In addition, stroke patients with NBTE had a very high risk of mortality and stroke events during a 6-month follow-up.

The pathomechanism of NBTE remains unknown. Autopsy studies in patients with NBTE have shown that cardiac vegetation is mainly composed of platelets \[[@b21-jos-2020-00619]\], and examinations of thrombi retrieved during mechanical thrombectomy in stroke patients with NBTE have indicated very high platelet and low erythrocyte fractions \[[@b11-jos-2020-00619],[@b22-jos-2020-00619]\]. These studies suggest that platelet-mediated mechanisms play a key role in the development of cancer-associated NBTE. The role of platelets in cancer has been extensively studied; platelets play a crucial role in tumor growth and metastasis \[[@b23-jos-2020-00619]\].

Our study demonstrated that NBTE occurred exclusively in patients with metastasis. Platelets can contribute to tumor invasion and metastasis via several mechanisms. Platelets are essential for the survival of circulating tumor cells \[[@b24-jos-2020-00619]\], and these cells rapidly associate with platelets via their receptors and induce tumor cell-induced platelet aggregation (TCIPA) \[[@b25-jos-2020-00619]\]. This TCIPA is critical for tumor cell survival as platelets form a physical shield around tumor cells, protecting them from recognition and lysis by natural killer cells and shear-induced damage \[[@b26-jos-2020-00619],[@b27-jos-2020-00619]\]. These findings suggest that the association of tumor cells with platelets during metastasis may somehow contribute to the development of platelet-rich vegetation in NBTE.

Stroke patients with active cancer have a substantial risk of recurrent stroke. In a retrospective study, ischemic stroke recurred in 16% patients within 6 months of the initial stroke \[[@b15-jos-2020-00619]\]. In the present study cohort, ischemic stroke recurred in 21.6% patients and ICH developed in 0.8% patients. Particularly, 50% patients with NBTE developed stroke within 6 months, significantly higher than those without NBTE. Ninety percent of patients with NBTE had lesions involving multiple vascular territories, which suggests multiple embolization from the heart. Patients with NBTE may be prone to a high risk of multiple thromboembolism because the platelet-rich vegetation (thrombus) is attached to the fast-moving cardiac valves.

This study showed that mortality differed significantly among the three etiology categories of stroke patients with active cancer. During the 6 months of follow-up, 80% patients with NBTE died. However, less than one-third of the patients with a determined etiology died. Patients with a cryptogenic etiology had an intermediate risk of 6-month mortality. The high mortality in patients with NBTE may be associated with metastasis since all patients with NBTE had it. In our previous study, 67.1% stroke patients with metastatic cancer died within 6 months \[[@b20-jos-2020-00619]\], but the 6-month mortality in patients with NBTE was even higher. In the present study, mortality was also higher in patients who developed recurrent stroke; therefore, frequent stroke reoccurrence in patients with NBTE might also increase the risk of death.

In this study, patients with NBTE had higher D-dimer levels and more frequent multiple vascular territory involvement than those of patients with stroke of a determined etiology. These are known characteristics of cancer-related stroke \[[@b3-jos-2020-00619]\]. Our findings suggest that some features of cancer-related stroke may be associated with NBTE \[[@b28-jos-2020-00619],[@b29-jos-2020-00619]\]. Patients with a cryptogenic etiology had intermediate characteristics between those with NBTE and those with a determined etiology. Although NBTE is often not diagnosed despite TEE being performed \[[@b30-jos-2020-00619]\], NBTE has been suggested as the likely cause of cryptogenic stroke in many patients with cancer \[[@b29-jos-2020-00619]\]. Therefore, undiagnosed NBTE may have been present in some patients with a cryptogenic etiology.

This study has several limitations. First, although patients were enrolled prospectively, analysis for this study was performed retrospectively at a single center. In addition, as the study hospital has a dedicated cancer center, the frequency of cancer, particularly that of advanced cancer or metastasis, might be higher than that in other more general hospitals. Second, although most patients (85%) with active cancer underwent echocardiography, TEE (the gold standard for diagnosis of vegetation \[[@b30-jos-2020-00619],[@b31-jos-2020-00619]\]) was used in only 60.4%. Although TEE is one of the routine evaluations in our protocol, it was impractical to perform TEE in all patients (it is semi-invasive and requires patient cooperation and informed consent). Vegetation is often invisible on TTE, and even when using TEE, a small vegetation may not be detected. Therefore, the presence of NBTE in this study might have been underestimated. Third, the antithrombotic treatment for stroke prevention in our study population was not controlled. Therefore, the influence of preventive treatment on stroke recurrence is unknown. Finally, our explanation on the role of platelets in metastasis and development of NBTE is speculative.

Conclusions
===========

NBTE should be suspected as a potential mechanism of stroke in patients with metastatic cancer, particularly in those without determinable etiologies. We also showed that patients with NBTE have a very high short-term risk of recurrent stroke and mortality. In addition, mortality was higher in patients who developed recurrent stroke. In this regard, efforts are necessary to reduce the risk of stroke recurrence in these patients. Further studies are necessary to determine optimal preventive treatment in stroke patients with cancer-associated NBTE.

**Disclosure**

The authors have no financial conflicts of interest.

This study was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2018R1A2A3074996), the National Research Foundation of Korea grant funded by the Korean government (NRF-2017R1C1B5076990), and a faculty research grant of Yonsei University College of Medicine (6-2018-0185).

Supplementary materials
=======================

Supplementary materials related to this article can be found online at <https://doi.org/10.5853/jos.2020.00619>.

###### 

Comparison between patients with and without transesophageal echocardiography
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Etiologic mechanisms of stroke in 129 patients with a determined etiology

![Kaplan-Meyer analysis of (A) mortality, (B) stroke events, and (C) composite outcomes of mortality and stroke events during the 6-month follow-up. Bonferroni's correction was performed for intergroup comparisons. NBTE, nonbacterial thrombotic endocarditis.](jos-2020-00619f1){#f1-jos-2020-00619}

###### 

Comparison of baseline characteristics according to stroke etiology

  Characteristic                            NBTE (n=20)                             Cryptogenic etiology (n=96)   Determined etiology (n=129)   *P*                                                                                                                                                      
  ----------------------------------------- --------------------------------------- ----------------------------- ----------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------
  Demographics                                                                                                                                                                                                                                                                                           
                                            Age (yr)                                61.5±8.7                      68.1±10.1                     70.3±10.9                                                                                                                                                0.002^[\*](#tfn1-jos-2020-00619){ref-type="table-fn"},[†](#tfn2-jos-2020-00619){ref-type="table-fn"}^
                                            Male sex                                9 (45.0)                      43 (44.8)                     84 (65.1)                                                                                                                                                0.006^[‡](#tfn3-jos-2020-00619){ref-type="table-fn"}^
  Risk factors                                                                                                                                                                                                                                                                                           
                                            Hypertension                            10 (50.0)                     57 (59.4)                     92 (71.3)                                                                                                                                                0.062
                                            Diabetes mellitus                       5 (25.0)                      25 (26.0)                     47 (36.4)                                                                                                                                                0.204
                                            Dyslipidemia                            5 (25.0)                      13 (13.5)                     28 (21.7)                                                                                                                                                0.228
                                            Atrial fibrillation                     5 (25.0)                      0 (0)                         46 (35.7)                                                                                                                                                \<0.001^[\*](#tfn1-jos-2020-00619){ref-type="table-fn"},[‡](#tfn3-jos-2020-00619){ref-type="table-fn"}^
                                            Current smoker                          1 (5.0)                       12 (12.5)                     17 (13.2)                                                                                                                                                0.581
                                            Patent foramen ovale                    3 (15.0)                      21 (21.9)                     26 (20.2)                                                                                                                                                0.782
  Body mass index (kg/m^2^)                 22.3±2.9                                22.8±3.5                      22.5±3.6                      0.676                                                                                                                                                    
  Medications prior to admission                                                                                                                                                                                                                                                                         
                                            Antiplatelets                           3 (15.0)                      19 (19.8)                     39 (30.2)                                                                                                                                                0.129
                                            Anticoagulants                          3 (15.0)                      4 (4.2)                       15 (11.6)                                                                                                                                                0.066
                                            Statin                                  7 (35.0)                      18 (18.8)                     37 (28.7)                                                                                                                                                0.138
  Medications mainly used after admission                                                                                                       0.048^[‡](#tfn3-jos-2020-00619){ref-type="table-fn"}^                                                                                                    
                                            Antiplatelets                           6 (30.0)                      56 (58.3)                     73 (56.6)                                                                                                                                                
                                            Anticoagulants                          12 (60.0)                     31 (32.3)                     49 (38.0)                                                                                                                                                
                                            Both antiplatelets and anticoagulants   1 (5.0)                       2 (2.1)                       5 (3.9)                                                                                                                                                  
                                            No medication                           1 (5.0)                       7 (7.3)                       2 (1.6)                                                                                                                                                  
  Initial NIHSS score                       7 (3--12)                               5 (2--10)                     5 (1--12)                     0.547                                                                                                                                                    
  Reperfusion therapy                       6 (30.0)                                12 (12.6)                     28 (21.7)                     0.095                                                                                                                                                    
  Multiple territory involvement            18 (90.0)                               62 (64.6)                     47 (36.4)                     \<0.001^[†](#tfn2-jos-2020-00619){ref-type="table-fn"},[‡](#tfn3-jos-2020-00619){ref-type="table-fn"}^                                                   
  Laboratory findings                                                                                                                                                                                                                                                                                    
                                            Hemoglobin (g/dL)                       11.2±1.6                      10.8±2.0                      11.7±2.8                                                                                                                                                 0.036^[‡](#tfn3-jos-2020-00619){ref-type="table-fn"}^
                                            White blood cells (×10^9^/L)            10.4±5.1                      7.8±3.9                       8.1±4.2                                                                                                                                                  0.041^[\*](#tfn1-jos-2020-00619){ref-type="table-fn"}^
                                            Platelets (×10^9^/L)                    133±82                        201±113                       237±118                                                                                                                                                  \<0.001^[\*](#tfn1-jos-2020-00619){ref-type="table-fn"},[†](#tfn2-jos-2020-00619){ref-type="table-fn"}^
                                            D-dimer (mg/L)                          7.4±6.5                       4.8±9.0                       1.9±2.8                                                                                                                                                  \<0.001^[†](#tfn2-jos-2020-00619){ref-type="table-fn"},[‡](#tfn3-jos-2020-00619){ref-type="table-fn"}^
                                            Fibrinogen (g/L)                        2.6±1.6                       3.3±1.4                       3.5±1.3                                                                                                                                                  0.013^[†](#tfn2-jos-2020-00619){ref-type="table-fn"}^
  Metastatic cancer                         20 (100.0)                              67 (69.8)                     63 (48.8)                     \<0.001^[\*](#tfn1-jos-2020-00619){ref-type="table-fn"},[†](#tfn2-jos-2020-00619){ref-type="table-fn"},[‡](#tfn3-jos-2020-00619){ref-type="table-fn"}^   
  Cancer type                                                                                                                                   0.118                                                                                                                                                    
                                            Colorectal                              2 (10.0)                      11 (11.5)                     19 (14.7)                                                                                                                                                
                                            Gastric/esophageal                      3 (15.0)                      14 (14.6)                     27 (20.9)                                                                                                                                                
                                            Hepatobiliary                           6 (30.0)                      20 (20.8)                     12 (9.3)                                                                                                                                                 
                                            Pancreas                                4 (20.0)                      9 (9.4)                       9 (7.0)                                                                                                                                                  
                                            Lung                                    1 (5.0)                       21 (21.9)                     24 (18.6)                                                                                                                                                
                                            Bladder/urinary tract                   2 (10.0)                      3 (3.1)                       6 (4.7)                                                                                                                                                  
                                            Female genital organ                    1 (5.0)                       5 (5.2)                       6 (4.7)                                                                                                                                                  
                                            Others                                  1 (5.0)                       13 (13.5)                     26 (20.2)                                                                                                                                                

Values are presented as mean±standard deviation, number (%), or median (interquartile range).

NBTE, nonbacterial thrombotic endocarditis; NIHSS, National Institutes of Health Stroke Scale.

NBTE vs. Cryptogenic, *P*\<0.05;

NBTE vs. Determined, *P*\<0.05;

Cryptogenic vs. Determined, *P*\<0.05.

###### 

Causes of death and type of stroke event according to stroke etiology

  Variable                                     NBTE (n=20)   Cryptogenic etiology (n=96)   Determined etiology (n=129)   *P*
  -------------------------------------------- ------------- ----------------------------- ----------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------
  Composite outcomes of mortality and stroke   18 (90)       59 (61.5)                     50 (38.8)                     \<0.001^[\*](#tfn4-jos-2020-00619){ref-type="table-fn"},[†](#tfn5-jos-2020-00619){ref-type="table-fn"},[‡](#tfn6-jos-2020-00619){ref-type="table-fn"}^
  Mortality                                    16 (80)       52 (54.2)                     32 (32.6)                     \<0.001^[†](#tfn5-jos-2020-00619){ref-type="table-fn"},[‡](#tfn6-jos-2020-00619){ref-type="table-fn"}^
  Causes of death                                                                                                        0.307
   Cancer-related                              13 (81.2)     43 (82.7)                     27 (64.3)                     
   Stroke-related                              2 (12.5)      7 (13.5)                      12 (28.6)                     
   Other/unknown cause                         1 (6.3)       2 (3.8)                       3 (7.1)                       
  Any stroke events                            10 (50)       24 (25.0)                     21 (16.3)                     \<0.003^[†](#tfn5-jos-2020-00619){ref-type="table-fn"}^
  Stroke type                                                                                                            
   Cerebral infarction                         10 (100)      23 (95.8)                     20 (95.2)                     
   Intracerebral hemorrhage                    0 (0)         1 (4.2)                       1 (4.8)                       

Values are presented as number (%).

NBTE, nonbacterial thrombotic endocarditis.

NBTE vs. Cryptogenic, *P*\<0.05;

NBTE vs. Determined, *P*\<0.05;

Cryptogenic vs. Determined, *P*\<0.05.

###### 

Comparison of characteristics between patients with and without mortality/stroke events

  Characteristic                            No events (n=118)   Events (n=127)   *P*
  ----------------------------------------- ------------------- ---------------- ---------
  Demographics                                                                   
   Age (yr)                                 68.4±9.9            69.0±11.4        0.664
   Male sex                                 80 (67.8)           56 (44.1)        \<0.001
  Risk factors                                                                   
   Hypertension                             79 (66.9)           80 (63.0)        0.607
   Diabetes mellitus                        39 (33.1)           38 (29.9)        0.697
   Dyslipidemia                             27 (22.9)           19 (15.0)        0.155
   Atrial fibrillation                      26 (22.0)           25 (19.7)        0.768
   Current smoker                           20 (16.9)           10 (7.9)         0.049
  Body mass index (kg/m^2^)                 23.2±3.2            22.0±3.8         0.010
  Metastatic cancer                         42 (35.6)           108 (85.0)       \<0.001
  Cancer type                                                                    0.020
   Colorectal                               19 (16.1)           13 (10.2)        
   Gastric/esophageal                       22 (18.6)           22 (17.3)        
   Hepatobiliary                            13 (11.0)           25 (19.7)        
   Pancreas                                 5 (4.2)             17 (13.4)        
   Lung                                     21 (17.8)           25 (19.7)        
   Bladder/urinary tract                    8 (6.8)             3 (2.4)          
   Female genital organ                     5 (4.2)             7 (5.5)          
   Others                                   25 (21.2)           15 (11.8)        
  Initial NIHSS score                       3 (1--10)           6 (2--11.5)      0.007
  Reperfusion therapy                       25 (21.2)           21 (16.7)        0.460
  Multiple vascular territory involvement   36 (30.5)           91 (71.7)        \<0.001
  Stroke etiology                                                                \<0.001
   NBTE                                     2 (10.0)            18 (90.0)        
   Cryptogenic                              37 (38.5)           59 (61.5)        
   Determined                               79 (61.2)           50 (38.8)        
  Laboratory findings                                                            
   Hemoglobin (g/dL)                        11.6±2.1            11.0±2.7         0.033
   White blood cells (×10^9^/L)             7.5±3.7             8.9±4.5          0.008
   Platelets (×10^9^/L)                     243±112             188±116          \<0.001
   D-dimer (mg/L)                           1.1±1.5             5.7±8.3          \<0.001
   Fibrinogen (g/L)                         3.6±1.2             3.2±1.5          0.021

Values are presented as mean±standard deviation, number (%), or median (interquartile range).

NIHSS, National Institutes of Health Stroke Scale; NBTE, nonbacterial thrombotic endocarditis.

###### 

Cox models for 6-month composite outcomes of mortality/stroke events

  Variable                                                                                   Univariate analysis            Multivariate analysis                                                                                               
  ------------------------------------------------------------------------------------------ ------------------------------ ----------------------- ---------------------- ---------------------- ---------------------- ---------------------- -------
  Demographics                                                                                                                                                                                                                                  
                                                                                             Age (yr)                       0.999 (0.982--1.017)    0.931                  1.015 (0.996--1.034)   0.137                  1.011 (0.992--1.030)   0.269
                                                                                             Male sex                       0.471 (0.331--0.669)    \<0.001                0.540 (0.347--0.851)   0.007                  0.520 (0.333--0.810)   0.004
  Risk factors                                                                                                                                                                                                                                  
                                                                                             Hypertension                   0.841 (0.587--1.206)    0.347                                                                                       
                                                                                             Diabetes mellitus              0.877 (0.600--1.282)    0.498                                                                                       
                                                                                             Dyslipidemia                   0.665 (0.408--1.083)    0.101                  0.878 (0.519--1.463)   0.625                  0.948 (0.561--1.601)   0.840
                                                                                             Atrial fibrillation            0.902 (0.582--1.396)    0.643                                                                                       
                                                                                             Current smoker                 0.500 (0.262--0.955)    0.036                  0.938 (0.429--1.807)   0.862                  0.856 (0.418--1.753)   0.670
  Body mass index (kg/m^2^)                                                                  0.927 (0.878--0.979)           0.007                   0.926 (0.869--0.980)   0.012                  0.929 (0.875--0.986)   0.015                  
  Stroke etiology                                                                                                                                                                                                                               
                                                                                             Determined                     Reference                                      Reference                                                            
                                                                                             Cryptogenic                    1.976 (1.355--2.882)    \<0.001                1.447 (0.938--2.218)   0.090                                         
                                                                                             NBTE                           4.099 (2.371--7.086)    \<0.001                1.941 (1.052--3.690)   0.038                                         
  Medications mainly used after admission^[\*](#tfn7-jos-2020-00619){ref-type="table-fn"}^                                                                                                                                                      
                                                                                             Antiplatelets                  Reference                                      Reference                                     Reference              
                                                                                             Anticoagulants                 1.810 (1.277--2.567)    0.001                  1.353 (0.915--1.999)   0.130                  0.958 (0.644--1.427)   0.834
  Presence of metastasis                                                                     5.332 (3.264--8.708)           \<0.001                                                               2.870 (1.648--4.996)   \<0.001                
  Cancer type                                                                                                                                                                                                                                   
                                                                                             Colorectal                     1.113 (0.530--2.339)    0.778                  0.694 (0.326--1.565)   0.362                  0.796 (0.360--1.761)   0.573
                                                                                             Gastric/esophageal             1.521 (0.789--2.932)    0.210                  1.415 (0.675--2.839)   0.342                  1.399 (0.682--2.868)   0.359
                                                                                             Hepatobiliary                  2.196 (1.157--4.167)    0.016                  1.522 (0.745--2.997)   0.236                  1.312 (0.649--2.656)   0.450
                                                                                             Pancreas                       2.812 (1.402--5.638)    0.004                  1.093 (0.513--2.460)   0.826                  0.767 (0.339--1.734)   0.523
                                                                                             Lung                           1.628 (0.858--3.087)    0.136                  1.330 (0.670--2.568)   0.404                  1.084 (0.550--2.133)   0.816
                                                                                             Bladder/urinary tract          0.648 (0.188--2.238)    0.493                  0.686 (0.201--2.788)   0.576                  1.120 (0.293--4.280)   0.869
                                                                                             Female genital organ           2.059 (0.839--5.052)    0.115                  1.180 (0.477--3.289)   0.738                  1.115 (0.424--2.936)   0.825
                                                                                             Others                         Reference                                      Reference                                     Reference              
  Initial NIHSS score                                                                        1.031 (1.004--1.058)           0.024                   1.023 (0.994--1.056)   0.140                  1.028 (0.998--1.060)   0.071                  
  Reperfusion therapy                                                                        0.808 (0.506--1.291)           0.372                                                                                                               
  Multiple vascular territory involvement                                                    3.662 (2.482--5.403)           \<0.001                                                               2.524 (1.570--4.058)   \<0.001                
  Laboratory findings                                                                                                                                                                                                                           
                                                                                             Hemoglobin (g/dL)              0.918 (0.847--0.994)    0.034                  0.960 (0.864--1.046)   0.415                  1.007 (0.920--1.102)   0.879
                                                                                             White blood cells (×10^9^/L)   1.061 (1.020--1.104)    0.004                  1.095 (1.040--1.145)   \<0.001                1.094 (1.040--1.151)   0.001
                                                                                             Platelets (×10^9^/L)           0.996 (0.994--0.998)    \<0.001                0.997 (0.995--0.999)   0.003                  0.997 (0.996--0.999)   0.006
                                                                                             D-dimer (mg/L)                 1.078 (1.061--1.095)    \<0.001                1.053 (1.028--1.078)   \<0.001                1.033 (1.006--1.062)   0.018
                                                                                             Fibrinogen (g/L)               0.998 (0.996--0.999)    0.002                  0.999 (0.998--1.001)   0.480                  0.999 (0.997--1.001)   0.174

HR, hazard ratio; CI, confidence interval; NBTE, nonbacterial thrombotic endocarditis; NIHSS, National Institutes of Health Stroke Scale.

Excluded eight patients with both antiplatelet and anticoagulant, 10 patients without antithrombotics.
